收藏切换
A preliminary analysis of the new requirements in ICH E6 (R3) from a verification perspective and their implications for clinical trial verification
收藏切换
PDF
Yuan WANG, Yu-yao WANG, Rong GAO
Chinese Journal of Clinical Pharmacology | 2026, 42(10) : 1469 - 1473
Less
收藏切换
Chinese Journal of Clinical Pharmacology | 2026, 42(10): 1469-1473
Regulatory Science Column
A preliminary analysis of the new requirements in ICH E6 (R3) from a verification perspective and their implications for clinical trial verification
Full
Yuan WANG, Yu-yao WANG, Rong GAO
Affiliations
  • Center for Food and Drug Inspection, National Medical Products Administration, Beijing 100163, China
Published: 2026-05-28 doi: 10.13699/j.cnki.1001-6821.2026.10.019
Outline
收藏切换

The evolution of the ICH E6(R3) guideline heralds a new era for global Good Clinical Practice (GCP), centered on "participant-centricity" and "Quality by Design". From the perspective of China′s clinical trial regulatory inspection, this article provides a systematic comparative analysis of the transformative changes introduced by E6(R3) versus E6(R2) across seven key dimensions: core principles, trial design, ethical review, safety monitoring, vendor management, sponsor quality management, and data governance. The study concludes that these changes necessitate a fundamental paradigm shift in China′s registration inspection approach—moving from traditional "compliance verification" to an in-depth "assessment of system effectiveness" and "design rationality". To address this challenge, regulatory authorities must take the lead in comprehensively upgrading inspection philosophies, inspector competencies, technical tools, and evaluation standards. This will guide the clinical trial ecosystem in China towards high-quality and sustainable development, ensuring the effective protection of participants′ rights, safety, and welfare.

ICH E6(R3)  /  GCP  /  clinical trial inspection  /  regulatory science  /  quality by design  /  proportionate risk  /  fit for purpose
Yuan WANG, Yu-yao WANG, Rong GAO. A preliminary analysis of the new requirements in ICH E6 (R3) from a verification perspective and their implications for clinical trial verification[J]. Chinese Journal of Clinical Pharmacology, 2026 , 42 (10) : 1469 -1473 . DOI: 10.13699/j.cnki.1001-6821.2026.10.019
Year 2026 volume 42 Issue 10
PDF
176
35
Cite this Article
BibTeX
Article Info
doi: 10.13699/j.cnki.1001-6821.2026.10.019
  • Receive Date:2026-04-27
  • Online Date:2026-08-06
  • Published:2026-05-28
Article Data
Affiliations
History
  • Received:2026-04-27
Affiliations
    Center for Food and Drug Inspection, National Medical Products Administration, Beijing 100163, China
References
Share
https://castjournals.cast.org.cn/joweb/zglcylxzz/EN/10.13699/j.cnki.1001-6821.2026.10.019
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT